Zobrazeno 1 - 10
of 76
pro vyhledávání: ''
Autor:
Jill M Butterfield-Cowper
Publikováno v:
Annals of Pharmacotherapy. 55:846-855
Background: The optimal daptomycin dose for vancomycin-resistant Enterococcus faecium remains unclear. Dosing of 8 to 12 mg/kg/d has been recommended to improve outcomes, but literature suggests fixed dosing may improve methicillin-resistant Staphylo
Autor:
Brian L. Erstad
Publikováno v:
Annals of Pharmacotherapy. 55:798-804
Objectives The purpose of this critical narrative review is to discuss common indications for ordering serum albumin levels in adult critically ill patients, evaluate the literature supporting these indications, and provide recommendations for the ap
Publikováno v:
Annals of Pharmacotherapy. 54:1243-1251
Objective: To review the current literature describing pharmacology, pharmacokinetics/pharmacodynamics (PK/PD), efficacy, and safety of linezolid and daptomycin for the treatment of central nervous system (CNS) infections caused by vancomycin-resista
Autor:
Renee D Pitt, Sarah E Yost, Meryl Biksacky, Whitney Mortensen, Sophia Entringer, Shannon Inglet, Anh Lian, Bradly Winter
Publikováno v:
Annals of Pharmacotherapy. 54:1109-1143
Objective: To compile and synthesize the available literature describing medical cannabis use across various disease states. Data Sources: PubMed, EBSCO, and Google Scholar searches were conducted using MeSH and/or keywords. Study Selection and Data
Publikováno v:
Annals of Pharmacotherapy. 54:1021-1029
Objective: To review the 3 anti-inflammatory drugs, canakinumab, colchicine, and methotrexate, that have been investigated in major clinical trials for treating patients with atherosclerotic cardiovascular disease (ASCVD). Data Sources: An Ovid MEDLI
Publikováno v:
Annals of Pharmacotherapy. 52:910-919
Objective: To determine the pharmacological treatment methods available to anemic Jehovah’s Witnesses (JW). Data Sources: MEDLINE and PubMed were searched from inception through February 2018 using the search terms Jehovah’s Witnesses, treatment,
Autor:
David L. DeRemer, Morgan E Gwynn
Publikováno v:
Annals of Pharmacotherapy. 52:60-68
Objective: To summarize and evaluate immunotherapy agents targeting programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) recently approved for the treatment of metastatic urothelial carcinomas (UC). Data Sources: A literature
Autor:
Gregory S. Calip, Todd A. Lee, Min J. Joo, Glen T. Schumock, A. Simon Pickard, Jennifer C. Samp
Publikováno v:
Annals of Pharmacotherapy. 51:945-953
Background: The recent approval of several fixed-dose combination long-acting β2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) products has increased the use of dual bronchodilators in the treatment of chronic obstructive pulmonary dis
Autor:
Sarah E. Petite
Publikováno v:
Annals of Pharmacotherapy. 51:696-705
Objective: To compare the available literature regarding the use of long-acting muscarinic antagonist (LAMA)/long-acting β2 agonists (LABA) and inhaled corticosteroid (ICS)/LABA combination inhaler therapy in chronic obstructive pulmonary disease (C
Autor:
Lisa A. Scherkenbach, Janice L. Stumpf
Publikováno v:
Annals of Pharmacotherapy. 50:60-69
Objective: To review the literature evaluating methotrexate as a treatment option for Crohn’s disease (CD) in pediatric patients. Data Sources: A search of PubMed electronic database (1966 to August 2015) and secondary resources was performed using